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Abstract
Purpose—In studies where [11C]raclopride (RAC) PET is used to assess changes in striatal 
dopamine, it is important to control for cognitive states, such as drug craving, that could alter 
dopamine levels. In cigarette-smokers, transdermal nicotine patches (TNP) can control nicotine 
craving, but the effects of nicotine patches on RAC binding are unknown. Thus, we sought to 
determine the test-retest reliability of RAC binding in the presence of nicotine patches.
Methods—Eleven male smokers were scanned twice with RAC on separate days while wearing 
transdermal nicotine patches.
Results—Across the striatum, test-retest variability was 7.63 ± 5.88; percent change in binding 
potential was 1.11 ± 9.83; and the intraclass correlation coefficient was 0.91 (p < 0.0001).
Conclusions—Baseline RAC binding is highly reproducible in smokers wearing nicotine 
patches. This suggests that transdermal nicotine patches are an acceptable method for controlling 
cigarette craving during studies that utilize RAC to examine changes in dopamine.
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Introduction
It is possible to assess in vivo changes in relative dopamine levels with PET and 
dopaminergic radioligands that are sensitive to alterations in endogenous dopamine 
concentration [1–4] (e.g., [11C]raclopride, [18F]fallypride, and [11C]FLB). The goal of such 
studies is the comparison of dopamine D2 receptor availability during a test condition 
relative to a baseline or resting condition, with the difference in D2 signal between these two 
states attributed to changes in dopamine levels. There are many types of challenge 
paradigms (cognitive, motor, pharmacologic), methods of PET acquisition (single-bolus, 
bolus-plus-infusion) and study designs (one or two scans). Regardless of the scientific 
question being asked, or the particulars of the methodological approach, all experiments 
share a critical assumption: within subjects, the baseline state represents a stable comparator 
for the challenge condition [2, 5]. Unfortunately, this assumption can be easily violated by 
transient changes in cognitive states that may alter dopamine [1–2, 5]. When possible, it 
would be desirable to control internal states that may contribute to confounding 
measurements of D2 availability.
Several studies indicate that the internal state of drug craving is related to striatal dopamine 
levels [6–10]. For example, both Volkow et al. [6] and Wong et al. [7] presented cocaine 
users with cocaine-related cues, and found that cue-induced striatal dopamine release 
correlated with self-reported cue-induced craving. This evidence strongly supports the 
concept that increases in striatal dopamine levels are related to drug craving. In 2004, Heinz 
and colleagues [10] reported decreased D2 availability in the ventral striatum was negatively 
correlated with alcohol craving severity. It is reasonable to view lower D2 availability as a 
function of higher dopamine levels, and therefore this report is consistent with the idea that 
higher dopamine concentration may be associated with drug craving. On the other hand, 
Brody et al. [8–9] reported that smoking-induced reductions in BPND were associated with 
decreased craving for cigarettes, and proposed that increases in dopamine alleviate cigarette 
craving. In this case, however, the presence of chemosensory sensations and habitual motor 
routines of cigarette smoking may have increased DA independently of craving. Thus, in 
studies of populations with high rates of cigarette smoking, differences in nicotine 
withdrawal, and hence, craving between scan states present a serious challenge for data 
interpretation. Although transdermal nicotine patches could be used to control nicotine 
craving in smokers, it is not known whether stable baseline measurements of D2 availability 
are possible with nicotine patches. Therefore, the purpose of this study was to determine the 
reliability of striatal [11C]raclopride binding in the presence of transdermal nicotine patches 
in nicotine-dependent cigarette smokers.
Materials and Methods
All procedures were approved by the Indiana University Institutional Review Board, and 
performed in accordance with the ethical standards of the Belmont Report (United States 
Department of Health and Human Services, 1979). All subjects signed informed consent 
statements agreeing to participate in the study. Subjects were right-handed, social drinking 
male smokers who were in otherwise good physical and mental health. The absence of either 
alcohol abuse or dependence was confirmed by the Semi-Structured Assessment for the 
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Genetics of Alcoholism [11]. Subjects were excluded from participation if they endorsed 
recreational use of legal or illicit stimulants, painkillers, or sedatives, and/or consumption of 
> 1 marijuana cigarette (or equivalent) per week. Subject demographics are presented in 
Table 1. Nicotine dependence was assessed with the Fagerstrom Test for Nicotine 
Dependence [12].
Study Procedures
Procedures in this study are similar to those described previously [13]. Subjects underwent 
identical procedures on two separate days. Figure 1 illustrates the general timeline. Briefly, 
subjects presented to the Indiana Clinical Research Center at approximately 8 a.m. Shortly 
after arrival, an IV catheter was placed in an antecubital vein, and a transdermal nicotine 
patch was placed on the upper arm of each subject. Patch dose was based on subjects’ self-
report of cigarettes smoked per day (14 mg dose with 10 < 20 cigarettes per day; 21 mg dose 
with > 20 cigarettes). Two subjects were given a 14 mg patch; all others received a 21 mg 
patch. Subjects were given a full breakfast. As part of another study protocol, the morning of 
each study day, subjects received an IV alcohol infusion to a target breath alcohol 
concentration (BrAC) of 60 mg% using the Alcohol Clamp. The rationale and 
implementation of the alcohol clamping technique have been described in detail elsewhere 
[14–15]. The BrAC of all subjects returned to 0mg% prior to scanning. The Cigarette 
Withdrawal Scale (CWS) [16], a self-report Likert rating scale, was given periodically 
throughout each study day. Nicotine craving was measured with the second dimension on 
the CWS, which specifically captures the individual’s current subjective state of cigarette 
craving. There are 4 questions on this dimension, each with a 5-point scale; possible scores 
for cigarette craving range from 4 – 20. Ratings were taken upon arrival for the study (Time 
1), and before and after the resting (baseline) scan (Times 2 and 3). Eleven subjects 
completed both baseline RAC scans; a twelfth subject voluntarily withdrew from the study 
after the first RAC scan.
Scanning and Reconstruction Procedures
A magnetization prepared rapid gradient echo (MP-RAGE) magnetic resonance image 
(MRI) was acquired on all subjects using a Siemens 3T Trio for anatomic co-registration of 
PET data (see “Image Processing Procedures”).
Subjects received two baseline [11C]raclopride (RAC) scans in the early afternoon on two 
separate days. Time of injection was typically between 14:00 and 15:00. Breath alcohol 
concentration was 0mg% prior to scanning. The time between the end of the morning 
alcohol infusion and the baseline RAC scan was typically ~ 4 hours. RAC synthesis was 
completed as described previously [17]. RAC PET scans were acquired on a Siemens 
EXACT HR+ (3D mode; septa retracted). Prior to each PET scan, a 10-min transmission 
scan using three internal rod sources was acquired for attenuation correction. RAC PET 
scans were initiated with the IV infusion of 535 ± 45.4 MBq [11C]RAC (mass dose: 0.13 ± 
0.06 nmol/kg) over 1.5 min. Dynamic acquisition occurred for 50 min (time frames: 10 × 
30s, 45 × 60s). Dynamic PET images were generated using Siemens Fourier Rebinning 
(FORE) and filtered backprojection algorithms including corrections for attenuation, 
randoms, scatter, and deadtime.
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Image Processing Procedures
Image processing is similar to that described previously [13, 18]. MRI DICOM and RAC 
PET images were converted to Neuroimaging Informatics Technology Initiative (NIfTI) 
format (http://nifti.nimh.nih.gov/) using SPM5 (http://www.fil.ion.ucl.ac.uk/spm/). For each 
subject, dynamic PET data were co-registered to an early-time mean image to facilitate 
motion correction. The early mean PET image was co-registered to the MRI scan using the 
normalized mutual information algorithm in SPM5, with the transformation matrix from this 
co-registration subsequently applied to the motion-corrected dynamic PET data. Each 
subject’s MRI was spatially normalized to Montreal Neurological Institute (MNI) space. 
The transformation matrix obtained from the spatial normalization step was then applied to 
the motion-corrected, MRI-registered PET data from each subject.
All regions of interest (ROIs) were drawn on an average normalized MRI from all subjects, 
using MRIcron (http://www.sph.sc.edu/comd/rorden/mricron/). Striatal regions of interest 
(ROIs) consisted of the left and right ventral striatum, pre-commissural dorsal caudate, pre-
commissural dorsal putamen, post-commissural caudate, and post-commissural putamen, 
and were drawn according to specific anatomic landmarks [19–20]. For the reference region 
(tissue that contains little to no D2/D3 receptor density), an ROI was created that contained 
all cerebellar gray matter except for the vermis. Time-activity curves for each ROI were 
generated from the dynamic RAC data using the MarsBaR toolbox for SPM5 (http://
marsbar.sourceforge.net/). For each striatal ROI, D2/D3 receptor availability was indexed 
with BPND, the binding potential of [11C]raclopride calculated as bound tracer concentration 
relative to nondisplaceable tracer concentration [21]. Estimations of BPND were conducted 
using the multilinear reference tissue model (MRTM) [22].
Metrics of Test-Retest Reproducibility of Baseline RAC binding
The relative reproducibility of striatal BPND between Day 1 and Day 2 was examined with 
three calculations, test-retest variability (TRV) to assess relative variation in BPND between 
days as a function of the overall average BPND across days, percent change in BPND 
(ΔBPND) as a qualitative descriptor of differences in BPND between Day 1 and Day 2, and 
the intraclass correlation coefficient (ICC, one-way random effects model; as implemented 
in the PASW statistical package [23–24]), a metric of similarity between measurements on 
each day. TRV was calculated as: |BPday1 − BPday2|/[(BPday1 + BPday2)/2] [25–26]. ΔBP 
between Day 1 and Day 2 was calculated as: [(BPday1 − BPday2)/BPday1] × 100. Paired t-
tests were used to determine if striatal BPND was significantly different between scan days.
Other Statistical Tests
Independent t-tests were used to test for differences in injected radioactivity and injected 
mass dose between scan days. To examine the stability of cigarette craving (CWS dimension 
2 score), repeated-measures ANOVA (2 days × 3 time points) was used to test for effects of 
scan day, time point, and day*time point.
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Results
RAC Scan Parameters
Average number of days between scans was 11.7 ± 25.2 (range: 1 – 83 days). Injected 
radioactivity of RAC on Day 1 and Day 2 was 537 ± 54.7 and 533 ± 36.5 MBq, 
respectively. Corresponding mass doses were 0.13 ± 0.05 and 0.13 ± 0.06 nmol/kg. Injected 
radioactivity and mass doses were not significantly different between scan days.
Subject Data
The demographic characteristics of the subjects are shown in Table 1. Eight subjects 
reported smoking a full pack of cigarettes per day; two reported a half-pack, and one 
reported two packs per day. Three subjects tested positive for marijuana on both scan days; 
these subjects endorsed sporadic recreational use of marijuana within the previous month. 
One subject tested positive for opiates on Day 2 (subject had undergone a dental procedure, 
and reported taking a single tablet of acetaminophen and No. 3 codeine phosphate two days 
prior). Two of these subjects had test-retest variability for striatal RAC binding well within 1 
s.d. of the sample average (7.6 ± 5.9%; Table 2); the other was within 1.5 s.d. of the mean 
TRV.
Exact timing of patch placement was not available for one subject on Day 1. Across the 
remaining data points (n = 21), the interval between patch placement and resting scan was 
5.9 ± 0.9 hours. Ratings for the CWS were unavailable for one subject at both Day 1-Time 2 
and Day 2-Time 3; for one subject at Day 2- Time 2; and for one subject at Day 2-Time 3. 
Cigarette craving scores are presented in Figure 1. Repeated-measures ANOVA indicated 
that the CWS rating was stable within subjects, i.e., there were no main effects of day or 
timepoint, and no day*timepoint interaction.
Test-Retest Reproducibility of Resting RAC Signal
BPND values for both scan days, percent change of BPND between days (%Δ), the test-retest 
variability (TRV), and intra-class correlation coefficients (ICC) are presented in Table 2.
Discussion
In the current sample of 11 otherwise healthy cigarette smokers, there was good 
reproducibility of striatal [11C]raclopride RAC binding in the presence of transdermal 
nicotine patches. Overall, our test-retest metrics (Table 2) comport well with literature 
values for single-bolus RAC studies in healthy control subjects ([25, 27–29]). The average 
striatal data were exceptionally stable, with slight variations in reliability between 
subregions. We chose to demonstrate test-retest reliability with three methods. The percent 
change in BPND between scans is the most commonly used parameter of effect size, and 
corresponds to the calculation most commonly used to describe relative changes in 
dopamine levels between conditions. Test-retest variability (TRV) quantifies the size of 
absolute variability across measurements. Both indices provide useful estimates of the effect 
sizes needed to achieve statistical significance with a two-scan dopamine challenge 
paradigm (although statistical significance is possible with smaller effect sizes). In this 
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study, these assessments of RAC test-retest reliability suggest a range of variability 
consistent with what others have reported when scanning the same individuals across days. 
Overall, the intra-class correlation (ICC) coefficient r-values in this study were also quite 
good, and indicate that estimations of BPND on Day 1 correlated well with measurements on 
Day 2. Lower ICC values were found in small regions that tend to have slightly noisier time-
activity curves, and hence more variable estimates of BPND.
One potential concern about the use of nicotine patches is the possibility that nicotine itself 
might cause measurable dopamine release [30–31]. Two human RAC studies by Brody et al. 
support this view [8–9]. However, those designs included the actual physical act of smoking 
cigarettes. When nicotine is delivered intranasally to humans, or intravenously to 
unanesthetized monkeys, there is no evidence of significant decreases in RAC binding [32–
33]. Taken together, these latter studies strongly suggest that nicotine itself does not release 
dopamine to levels measurable by RAC PET. It is also possible that the physical and sensory 
properties associated with cigarette smoking are the key components of the smoking-
induced dopamine release reported by Brody et al.
In this study, the administration of IV alcohol to subjects the morning of the RAC PET study 
may be an unintended source of variance in baseline RAC BPND. In our previous work, we 
found no evidence of alcohol-induced dopamine release in social drinkers [34–35]. 
However, healthy social drinkers do not typically expose themselves to alcohol shortly after 
breakfast. We cannot exclude the possibility that alcohol exposure early in the morning may 
have caused unpredictable changes in the dopamine tone of healthy social drinkers.
Another limitation of this study was the absence of test-retest values for striatal RAC 
binding in smokers without nicotine patches, which could have assessed any variability in 
baseline striatal BPND attributable to nicotine withdrawal. However, the most important 
assumption in a typical dopaminergic RAC PET challenge paradigm is that the within-
subject state of basal dopamine is stable. The present data demonstrate that it is possible to 
control nicotine craving (which is highly likely to alter endogenous dopamine) while 
keeping estimates of baseline D2 availability stable.
Conclusion
The presence of transdermal nicotine patches does not appear to affect the stability of 
baseline [11C]raclopride binding potential. We suggest that, in RAC challenge studies, the 
use of nicotine patches in smoking subjects is feasible to eliminate unwanted variance in D2 
availability caused by nicotine craving and concomitant alterations in striatal dopamine 
levels.
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Fig. 1. 
General outline of study day, starting with subject arrival at ~ 8:00 a.m. All times are 
approximate. CWS: Cigarette Withdrawal Scale; EtOH: alcohol; MRI: magnetic resonance 
imaging; RAC: [11C]raclopride. Additional details are given in the text.
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Fig. 2. 
Mean ± s.d. cigarette craving ratings from Day 1 (filled circles) and Day 2 (open triangles), 
and Times 1, 2, and 3 (please see Figure 1 for approximate timing of ratings). The x-axis 
crosses the y-axis at the value of 4 to denote that 4 is the lowest possible score on the index; 
for reference, 20 is the highest possible score. Craving ratings did not vary within subjects 
across either day or time point (see text for details).
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